Session » RA – Diagnosis, Manifestations, & Outcomes Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1358

A Step Towards Personalised Medicine – Development and Efficacy of Machine Learning Based Smart-Web Application for Prediction of Steroid Induced Hyperglycemia in Patients with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 1348

Analysis of Body Composition in Patients with Moderate-Severe Rheumatoid Arthritis Treated with Anti-TNF Drugs

10:30AM-12:30PM: Abstract Number: 1334

Assessing the Performance of Validated Frailty Instruments in Veterans with Rheumatoid Arthritis (RA)

10:30AM-12:30PM: Abstract Number: 1353

Association Between Frailty and Incident Cancer in Newly Diagnosed Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1356

Association Between Vascular Inflammation and Kidney Function in Patients with Rheumatoid Arthritis: Secondary Analysis of TARGET Trial

10:30AM-12:30PM: Abstract Number: 1359

Association of Coronary Artery Calcium Score and Growth Differentiation Factor 15 in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1327

Association of Rheumatoid Arthritis and Frailty Status with Mortality in Patients with Renal Cell Carcinoma

10:30AM-12:30PM: Abstract Number: 1328

Carpal Tunnel Syndrome Is an Early Unrecognized Feature of Rheumatoid Arthritis: A Population-Based Study

10:30AM-12:30PM: Abstract Number: 1340

Characteristics and Long-term Outcomes of Patients with Rheumatoid Arthritis and Concurrent Calcium Pyrophosphate Deposition Disease

10:30AM-12:30PM: Abstract Number: 1365

Clinical Conditions Associated with Genetic Predisposition to Rheumatoid Arthritis in Real-World Settings

10:30AM-12:30PM: Abstract Number: 1362

Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting

10:30AM-12:30PM: Abstract Number: 1333

Deciphering Variation in Real-World Early RA Outcomes: A Longitudinal Analysis of the Canadian Early Arthritis Cohort (CATCH) Study

10:30AM-12:30PM: Abstract Number: 1351

Development of Noninvasive Assessment Technology for Rheumatoid Arthritis Based on Contact Property Measurements

10:30AM-12:30PM: Abstract Number: 1331

Does Refractory Rheumatoid Arthritis Status Matter in Modeling Patient Global Assessment Trajectories over 20 Years in a Large US Registry?

10:30AM-12:30PM: Abstract Number: 1346

Early Diagnosis of Rheumatoid Arthritis: Role of Joint Ultrasound Assessment

10:30AM-12:30PM: Abstract Number: 1341

Evaluation of Width Range Index (WRI) and Neutrophil-to-Lymphocyte Ratio (NLR) in Assessing Disease Activity in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1332

Financial Distress and Its Determinants in Adults with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1344

Forced Vital Capacity Trajectories and Risk of Lung Transplant and ILD-Related Mortality Among Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 1337

Gender and Ethnic Differences (or Lack Thereof) in Perceived Disease Burden in RA

10:30AM-12:30PM: Abstract Number: 1355

Genetically-determined Variation in C-reactive Protein Impacts Disease Activity Assessment in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1338

Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 1343

Heightened Gout Risk in Patients with Rheumatoid Arthritis: A National Cohort Study

10:30AM-12:30PM: Abstract Number: 1360

Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment

10:30AM-12:30PM: Abstract Number: 1330

Increased Levels of F-calprotectin in Patients with Early Rheumatoid Arthritis at Diagnosis

10:30AM-12:30PM: Abstract Number: 1347

Interest of DAS28-γGT in Assessing Cardiovascular Risk Activity in Rheumatoid Arthritis in Routine Practice

10:30AM-12:30PM: Abstract Number: 1329

Investigating Predictors of Transfusion in Rheumatoid Arthritis and Osteoarthritis Patients Undergoing Knee Arthroplasty

10:30AM-12:30PM: Abstract Number: 1357

Kidney Function in Rheumatoid Arthritis: Estimating Glomerular Filtration Rate Using Creatinine versus Cystatin C in a Secondary Analysis of the TARGET Trial

10:30AM-12:30PM: Abstract Number: 1345

Long-term Changes in Coronary Calcium Score Levels Among Patients with Rheumatoid Arthritis: A Cohort Study

10:30AM-12:30PM: Abstract Number: 1364

Machine Learning-Driven Models for Disease Activity Prediction and Therapeutic Response Evaluation in Rheumatoid Arthritis Patients: An Analysis of Data from the Multicentre, Prospective, Egyptian Collage of Rheumatology (ECR) Study Group

10:30AM-12:30PM: Abstract Number: 1363

Prevalence and Predictors of Orthopaedic Surgery in Rheumatoid Arthritis After 12-Years’ Follow-Up (ESPOIR Cohort)

10:30AM-12:30PM: Abstract Number: 1350

Relationship Between Salivary and Stool Microbiome with Disease Activity and Vascular Function in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1324

Rheumatoid Arthritis Associated Interstitial Lung Disease – Patient Perceptions and Recommendations

10:30AM-12:30PM: Abstract Number: 1336

Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database

10:30AM-12:30PM: Abstract Number: 1325

The Association Between the Number of Teeth and All-Cause as Well as Cardiovascular Mortality Among Patients with RA: NHANES from 1999 to 2004

10:30AM-12:30PM: Abstract Number: 1354

The Association of Genetic Variation in PTPN22 and Rheumatoid Arthritis Disease Activity

10:30AM-12:30PM: Abstract Number: 1335

The Association of Patient-Reported Non-Articular Pain with Musculoskeletal Pain Diagnoses and RA Disease Activity in a Prospective Real-World Cohort of Patients with Early RA

10:30AM-12:30PM: Abstract Number: 1352

The Associations Between Genetic Factors and Rheumatoid Arthritis Treatment Patterns: Data from Two Large Healthcare Systems

10:30AM-12:30PM: Abstract Number: 1361

The Effect of Disease Activity on Cardiovascular Risk Varies According to Rheumatoid Factor and Anticitrullinated Protein Antibody Status in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1349

Two Composite Cytokine Scores Predict Flare and Drug-free Remission in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1342

Utility of Anti-Carbamylated Antibodies in Early Rheumatoid Arthritis in South Asian Population

10:30AM-12:30PM: Abstract Number: 1339

When Medications Fail: A Mixed Methods Study Evaluating the Experience and Health-Related Quality of Life (HRQOL) of Adults with Rheumatoid Arthritis Non-Responsive to Treatment

10:30AM-12:30PM: Abstract Number: 1326

Which Biomarkers Indicate Imminent Progression to Inflammatory Arthritis in High Risk CCP Positive Persons?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].